from a “neutral” rating to a “buy” rating and increased their price target for the company from $105.00 to $130.00 in a research report on Thursday, April 13th. from a “buy” rating to a “neutral” rating in a research report on Sunday, April 16th. BTIG Research downgraded Merck & Co., Inc. from $125.00 to $126.00 and gave the company an “outperform” rating in a research report on Tuesday, March 7th. Credit Suisse Group increased their price target on Merck & Co., Inc.
Wall Street Analyst Weigh InĪ number of brokerages recently commented on MRK. Merck & Co., Inc.’s dividend payout ratio is currently 57.03%.
This represents a $2.92 annualized dividend and a dividend yield of 2.67%. The ex-dividend date is Wednesday, June 14th. Stockholders of record on Thursday, June 15th will be issued a $0.73 dividend. The business also recently disclosed a quarterly dividend, which will be paid on Monday, July 10th. will post 6.95 EPS for the current fiscal year. On average, research analysts expect that Merck & Co., Inc. The company’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same quarter last year, the business posted $2.14 earnings per share. The business had revenue of $14.49 billion for the quarter, compared to the consensus estimate of $13.81 billion. had a return on equity of 37.92% and a net margin of 22.52%. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.06. ( NYSE:MRK – Get Rating) last released its quarterly earnings results on Thursday, April 27th. 76.60% of the stock is owned by hedge funds and other institutional investors. Morgan Stanley now owns 41,850,081 shares of the company’s stock valued at $4,643,267,000 after acquiring an additional 4,000,816 shares during the last quarter. Finally, Morgan Stanley increased its position in shares of Merck & Co., Inc. Renaissance Technologies LLC now owns 5,099,334 shares of the company’s stock valued at $418,400,000 after acquiring an additional 4,915,334 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Merck & Co., Inc. MD now owns 26,314,030 shares of the company’s stock valued at $2,919,542,000 after acquiring an additional 11,051,945 shares during the last quarter. MD increased its position in shares of Merck & Co., Inc.
in the fourth quarter worth approximately $2,736,293,000. Norges Bank purchased a new stake in shares of Merck & Co., Inc. Moneta Group Investment Advisors LLC now owns 39,327,490 shares of the company’s stock worth $4,363,385,000 after purchasing an additional 39,289,404 shares during the last quarter. Moneta Group Investment Advisors LLC raised its stake in shares of Merck & Co., Inc. Several other institutional investors and hedge funds have also recently modified their holdings of MRK. were worth $1,913,000 as of its most recent filing with the Securities & Exchange Commission. Parsec Financial Management Inc.’s holdings in Merck & Co., Inc. The fund owned 17,978 shares of the company’s stock after purchasing an additional 474 shares during the quarter. ( NYSE:MRK – Get Rating) by 2.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission.
0 kommentar(er)
